Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

2014: The Year of Digital Pharma?

January 23, 2014

2014 might be the year that pharma finally has to get really serious about digital, at least if the analysts are right. Peter Houston reports.

Innovation: The Moneyball Test

January 21, 2014

Successful innovation now has to align with key metrics of value—can an old baseball metaphor help guide the way?

Pharm Exec's Annual Industry Outlook 2014

January 21, 2014

For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive — muddling through is so yesterday.

Biosimilars or Bust

January 21, 2014

Where are the biosimilars to help cut costs as the first wave of biologics, or complex, small molecule respiratory drugs, for example, go off patent? They've arrived in Europe, but the U.S. lags...

Russia's Bet on Biopharma

January 21, 2014

Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector, writes William Looney.

Social Media: Have We Reached the Tipping Point?

January 20, 2014

FDA has released its draft guidance on the use of Interactive Promotional Media, finally providing the industry with substantial guidance on its use of digital media.

R&D in Transition

January 17, 2014

If R&D doesn't rebound, the growth prospects of R&D services providers will suffer, and even commercial CMOs will see fewer opportunities coming their way, writes Jim Miller.

Drugs, At What Cost?

January 15, 2014

As austerity, the patent cliff, and regulatory practices continue to shape the financial outlook for pharma, the key question is: What price can (or will) patients pay for the therapy?

The 7 Habits of Highly Effective Competitors

January 13, 2014

Biopharma's best companies provide valuable lessons for preparing, planning, and playing to win. Stan Bernard shows us how.

ADVERTISEMENT

Click here